USD 4.33
(1.64%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 181.36 Million USD | -1.27% |
2022 | 183.69 Million USD | -8.71% |
2021 | 201.22 Million USD | 35.59% |
2020 | 148.41 Million USD | -10.11% |
2019 | 165.1 Million USD | 41.55% |
2018 | 116.63 Million USD | 689.22% |
2017 | 14.77 Million USD | 30.46% |
2016 | 11.32 Million USD | 2620.33% |
2015 | 416.43 Thousand USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 179.66 Million USD | -0.44% |
2024 Q1 | 180.45 Million USD | -0.5% |
2023 Q4 | 181.36 Million USD | -2.38% |
2023 Q3 | 185.78 Million USD | 3.77% |
2023 FY | 181.36 Million USD | -1.27% |
2023 Q2 | 179.03 Million USD | -1.85% |
2023 Q1 | 182.4 Million USD | -0.7% |
2022 FY | 183.69 Million USD | -8.71% |
2022 Q4 | 183.69 Million USD | -8.59% |
2022 Q2 | 201.97 Million USD | 4.62% |
2022 Q3 | 200.94 Million USD | -0.51% |
2022 Q1 | 193.04 Million USD | -4.07% |
2021 Q4 | 201.22 Million USD | 11.02% |
2021 FY | 201.22 Million USD | 35.59% |
2021 Q1 | 161.88 Million USD | 9.08% |
2021 Q2 | 176.64 Million USD | 9.11% |
2021 Q3 | 181.24 Million USD | 2.61% |
2020 Q3 | 180.95 Million USD | 0.12% |
2020 FY | 148.41 Million USD | -10.11% |
2020 Q4 | 148.41 Million USD | -17.98% |
2020 Q2 | 180.73 Million USD | 7.55% |
2020 Q1 | 168.04 Million USD | 1.78% |
2019 FY | 165.1 Million USD | 41.55% |
2019 Q4 | 165.1 Million USD | 2.02% |
2019 Q3 | 161.83 Million USD | 11.7% |
2019 Q2 | 144.87 Million USD | 0.68% |
2019 Q1 | 143.89 Million USD | 23.37% |
2018 FY | 116.63 Million USD | 689.22% |
2018 Q3 | 13.13 Million USD | -21.55% |
2018 Q4 | 116.63 Million USD | 787.79% |
2018 Q2 | 16.74 Million USD | 5.24% |
2018 Q1 | 15.91 Million USD | 7.67% |
2017 Q1 | 10.99 Million USD | -2.98% |
2017 Q2 | 10.93 Million USD | -0.5% |
2017 Q3 | 13.54 Million USD | 23.87% |
2017 Q4 | 14.77 Million USD | 9.1% |
2017 FY | 14.77 Million USD | 30.46% |
2016 Q4 | 11.32 Million USD | 2.02% |
2016 FY | 11.32 Million USD | 2620.33% |
2016 Q2 | 609.71 Thousand USD | 0.0% |
2016 Q3 | 11.1 Million USD | 1721.25% |
2015 FY | 416.43 Thousand USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Collegium Pharmaceutical, Inc. | 947.87 Million USD | 80.867% |
Embecta Corp. | 2.03 Billion USD | 91.093% |
ANI Pharmaceuticals, Inc. | 471.67 Million USD | 61.549% |
Dynavax Technologies Corporation | 375.02 Million USD | 51.64% |
Esperion Therapeutics, Inc. | 660.79 Million USD | 72.554% |
Pacira BioSciences, Inc. | 704.25 Million USD | 74.248% |
PainReform Ltd. | 2.69 Million USD | -6639.576% |
Aquestive Therapeutics, Inc. | 163.9 Million USD | -10.651% |
Sunshine Biopharma, Inc. | 6.13 Million USD | -2853.971% |
SCYNEXIS, Inc. | 55.45 Million USD | -227.073% |
China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -1872.053% |
Cosmos Health Inc. | 30.25 Million USD | -499.494% |
Journey Medical Corporation | 56.49 Million USD | -221.0% |
Sunshine Biopharma, Inc. | 6.13 Million USD | -2853.971% |
Safety Shot Inc | 3.89 Million USD | -4559.814% |
Alpha Teknova, Inc. | 38.55 Million USD | -370.447% |
Intra-Cellular Therapies, Inc. | 136.87 Million USD | -32.506% |
Bright Green Corporation | 6.43 Million USD | -2717.01% |
Procaps Group, S.A. | 462.06 Million USD | 60.75% |
Theratechnologies Inc. | 98.63 Million USD | -83.864% |
Harrow Health, Inc. | 241.75 Million USD | 24.98% |
Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -1971.288% |
Biofrontera Inc. | 23.13 Million USD | -683.794% |
DURECT Corporation | 30.4 Million USD | -496.468% |
Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 62.795% |
Cronos Group Inc. | 43.73 Million USD | -314.674% |
OptiNose, Inc. | 194.33 Million USD | 6.676% |
Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 77.811% |
Kala Pharmaceuticals, Inc. | 48.44 Million USD | -274.367% |
RedHill Biopharma Ltd. | 20.97 Million USD | -764.529% |
Guardion Health Sciences, Inc. | 3.77 Million USD | -4707.942% |
Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -245.345% |
Radius Health, Inc. | 804.29 Million USD | 77.451% |
Universe Pharmaceuticals INC | 13.75 Million USD | -1218.581% |
ProPhase Labs, Inc. | 42.54 Million USD | -326.293% |
Phibro Animal Health Corporation | 725.54 Million USD | 75.003% |
Procaps Group S.A. | 462.06 Million USD | 60.75% |
Alvotech | 1.88 Billion USD | 90.366% |
TherapeuticsMD, Inc. | 14.02 Million USD | -1193.41% |
Viatris Inc. | 27.21 Billion USD | 99.334% |
Rockwell Medical, Inc. | 30.88 Million USD | -487.274% |
Aytu BioPharma, Inc. | 90.37 Million USD | -100.668% |
SIGA Technologies, Inc. | 57.97 Million USD | -212.816% |
Tilray Brands, Inc. | 892.11 Million USD | 79.671% |
Lifecore Biomedical, Inc. | 219.8 Million USD | 17.488% |
Shineco, Inc. | 47.6 Million USD | -280.999% |
PetIQ, Inc. | 645.22 Million USD | 71.892% |
Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -82520.54% |
Incannex Healthcare Limited | 5.83 Million USD | -3010.84% |
Neurocrine Biosciences, Inc. | 1.01 Billion USD | 82.209% |
Alimera Sciences, Inc. | 107.35 Million USD | -68.938% |
Silver Spike Investment Corp. | 3 Million USD | -5925.654% |
Assertio Holdings, Inc. | 148.41 Million USD | -22.198% |
Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -9465.683% |
Petros Pharmaceuticals, Inc. | 21.31 Million USD | -750.835% |
Clever Leaves Holdings Inc. | 7.02 Million USD | -2481.298% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | -2036.05% |
Avadel Pharmaceuticals plc | 173.38 Million USD | -4.6% |
Hempacco Co., Inc. | 18.82 Million USD | -863.543% |
Talphera, Inc. | 6.29 Million USD | -2783.339% |
Alvotech | 1.88 Billion USD | 90.366% |
Eagle Pharmaceuticals, Inc. | 172.6 Million USD | -5.076% |
Lantheus Holdings, Inc. | 835.25 Million USD | 78.287% |
Currenc Group, Inc. | 177.67 Million USD | -2.075% |
Kamada Ltd. | 109.96 Million USD | -64.922% |
Indivior PLC | 1.95 Billion USD | 90.705% |
Evoke Pharma, Inc. | 9.64 Million USD | -1779.772% |
Flora Growth Corp. | 17.22 Million USD | -953.083% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | -2036.05% |
Evolus, Inc. | 209.68 Million USD | 13.508% |
HUTCHMED (China) Limited | 536.38 Million USD | 66.188% |
Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 79.237% |
Akanda Corp. | 12.66 Million USD | -1331.555% |